Completed PHASE2 INTERVENTIONAL 2-arm NCT01197053

Epicutaneous Immunotherapy in Peanut Allergy in Children (ARACHILD)

ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Peanut Allergy

Interventions Epicutaneous Immunotherapy placebo of peanut

Updated 5 times since 2017 Last updated: Oct 18, 2015 Started: Aug 31, 2010 Primary completion: Feb 28, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01197053, this PHASE2 trial focuses on Peanut Allergy and remains completed. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
DBV Technologies

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France